Literature DB >> 18268089

Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria.

Robin Kobbe, Nadine Schreiber, Jürgen May, Thomas Jacobs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18268089      PMCID： PMC2292537          DOI： 10.1128/AAC.01428-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

1.  Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.

Authors:  Bruno Pradines; Marylin Torrentino-Madamet; Albin Fontaine; Maud Henry; Eric Baret; Joel Mosnier; Sébastien Briolant; Thierry Fusai; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

2.  Statin use and sepsis events [corrected] in patients with chronic kidney disease.

Authors:  Rajesh Gupta; Laura C Plantinga; Nancy E Fink; Michal L Melamed; Josef Coresh; Caroline S Fox; Nathan W Levin; Neil R Powe
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

3.  Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase.

Authors:  T Kita; M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

Review 4.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

5.  Prior statin therapy is associated with a decreased rate of severe sepsis.

Authors:  Yaniv Almog; Alexander Shefer; Victor Novack; Nimrod Maimon; Leonid Barski; Miruna Eizinger; Michael Friger; Lior Zeller; Abraham Danon
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

6.  Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.

Authors:  Bernd Lepenies; Klaus Pfeffer; Michelle A Hurchla; Theresa L Murphy; Kenneth M Murphy; Juliane Oetzel; Bernhard Fleischer; Thomas Jacobs
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

Review 7.  Statins and sepsis: multiple modifications at multiple levels.

Authors:  Marius Terblanche; Yaniv Almog; Robert S Rosenson; Terry S Smith; Daniel G Hackam
Journal:  Lancet Infect Dis       Date:  2007-05       Impact factor: 25.071

8.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes.

Authors:  P Grellier; A Valentin; V Millerioux; J Schrevel; D Rigomier
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 9.  Statins and the vascular endothelial inflammatory response.

Authors:  John Greenwood; Justin C Mason
Journal:  Trends Immunol       Date:  2007-01-02       Impact factor: 16.687

10.  Malarial anemia: of mice and men.

Authors:  Abigail A Lamikanra; Douglas Brown; Alexandre Potocnik; Climent Casals-Pascual; Jean Langhorne; David J Roberts
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113
View more
  11 in total

1.  Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs.

Authors:  Rina P M Wong; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

2.  Vascular endothelial growth factor (VEGF) and lovastatin suppress the inflammatory response to Plasmodium berghei infection and protect against experimental cerebral malaria.

Authors:  Miriam Canavese; Andrea Crisanti
Journal:  Pathog Glob Health       Date:  2015-09-21       Impact factor: 2.894

3.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

4.  Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.

Authors:  Carmen María Martín-Navarro; Jacob Lorenzo-Morales; Rubén P Machin; Atteneri López-Arencibia; José Manuel García-Castellano; Isabel de Fuentes; Brendan Loftus; Sutherland K Maciver; Basilio Valladares; José E Piñero
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

5.  Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.

Authors:  Véronique Parquet; Sébastien Briolant; Marylin Torrentino-Madamet; Maud Henry; Lionel Almeras; Rémy Amalvict; Eric Baret; Thierry Fusaï; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

6.  Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage.

Authors:  Zacharie Taoufiq; Paco Pino; Nadine N'dilimabaka; Issam Arrouss; Serge Assi; Florent Soubrier; Angelita Rebollo; Dominique Mazier
Journal:  Malar J       Date:  2011-02-28       Impact factor: 2.979

7.  Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.

Authors:  Jean-Baptiste Souraud; Sébastien Briolant; Jérome Dormoi; Joel Mosnier; Hélène Savini; Eric Baret; Rémy Amalvict; Raoulin Soulard; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2012-01-10       Impact factor: 2.979

8.  Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.

Authors:  Jérome Dormoi; Sébastien Briolant; Camille Desgrouas; Bruno Pradines
Journal:  Malar J       Date:  2013-04-15       Impact factor: 2.979

9.  Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.

Authors:  Nana O Wilson; Wesley Solomon; Leonard Anderson; John Patrickson; Sidney Pitts; Vincent Bond; Mingli Liu; Jonathan K Stiles
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.

Authors:  Jérôme Dormoi; Sébastien Briolant; Aurélie Pascual; Camille Desgrouas; Christelle Travaillé; Bruno Pradines
Journal:  Malar J       Date:  2013-08-30       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.